FIELD: medicine.
SUBSTANCE: group of inventions relates to methods for treating a patient who has undergone surgery and has short bowel syndrome. The methods include the use of a GLP-2 peptibody comprising the sequence of SEQ ID NO: 2 to treat a patient expected to develop short bowel syndrome after surgery, before surgery, during surgery, or within 48 hours after surgery.
EFFECT: inventions promote intestinal growth for several days or weeks after surgery by increasing the length of the villi and the depth of the crypts, which improves intestinal absorption and reduces the need for parenteral nutrition support.
30 cl, 6 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATMENT OF GASTROINTESTINAL DISORDERS | 2014 |
|
RU2763796C2 |
| METHODS AND COMPOSITIONS FOR GASTROENTERIC UPSET THERAPY | 2004 |
|
RU2353383C2 |
| METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISORDERS | 2004 |
|
RU2543350C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
